Literature DB >> 27999042

Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.

Adrián Sousa Dominguez1, M Teresa Perez-Rodríguez1, Andrés Nodar1, Lucía Martinez-Lamas2, Antonio Perez-Landeiro3, Manuel Crespo Casal1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27999042     DOI： 10.1093/jac/dkw526

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

1.  Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.

Authors:  Manuel Díaz-Cañestro; Leonor Periañez; Xavier Mulet; M Luisa Martin-Pena; Pablo A Fraile-Ribot; Ignacio Ayestarán; Asunción Colomar; Belén Nuñez; Maria Maciá; Andrés Novo; Vicente Torres; Javier Asensio; Carla López-Causapé; Olga Delgado; José Luis Pérez; Javier Murillas; Melchor Riera; Antonio Oliver
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-23       Impact factor: 3.267

2.  Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.

Authors:  Laura Escolà-Vergé; Carles Pigrau; Ibai Los-Arcos; Ángel Arévalo; Belen Viñado; David Campany; Nieves Larrosa; Xavier Nuvials; Ricard Ferrer; Oscar Len; Benito Almirante
Journal:  Infection       Date:  2018-03-28       Impact factor: 3.553

Review 3.  Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Authors:  Lynn Nguyen; Joshua Garcia; Katherine Gruenberg; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2018-06-06       Impact factor: 3.725

4.  Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.

Authors:  David M Livermore; Shazad Mushtaq; Daniele Meunier; Katie L Hopkins; Robert Hill; Rachael Adkin; Aiysha Chaudhry; Rachel Pike; Peter Staves; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

5.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

Review 6.  Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.

Authors:  Luigi Principe; Tommaso Lupia; Lilia Andriani; Floriana Campanile; Davide Carcione; Silvia Corcione; Francesco Giuseppe De Rosa; Roberto Luzzati; Giacomo Stroffolini; Marina Steyde; Giuliana Decorti; Stefano Di Bella
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-12

Review 7.  Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR).

Authors:  Z S Khankhel; R J Dillon; M Thosar; C Bruno; L Puzniak
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-10-03       Impact factor: 6.781

8.  Electrospun Fibers and Sorbents as a Possible Basis for Effective Composite Wound Dressings.

Authors:  Alan Saúl Álvarez-Suárez; Syed G Dastager; Nina Bogdanchikova; Daniel Grande; Alexey Pestryakov; Juan Carlos García-Ramos; Graciela Lizeth Pérez-González; Karla Juárez-Moreno; Yanis Toledano-Magaña; Elena Smolentseva; Juan Antonio Paz-González; Tatiana Popova; Lyubov Rachkovskaya; Vadim Nimaev; Anastasia Kotlyarova; Maksim Korolev; Andrey Letyagin; Luis Jesús Villarreal-Gómez
Journal:  Micromachines (Basel)       Date:  2020-04-22       Impact factor: 2.891
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.